SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Ingrevia inks pact to acquire 100% stake in Remidex Pharma

14 Mar 2026 Evaluate

Jubilant Ingrevia has entered into the Share Purchase Agreement with Remidex Pharma (Remidex) for acquisition of its 100% stake. After acquisition Remidex will become wholly owned subsidiary of the Company. 

This acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition Space building upon its leadership position in Vitamins (Vitamin B3 & B4). Cost of acquisition is Rs 16.5 crore subject to customary closing conditions. The said acquisition is expected to be completed in 30 days.  

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. 


Jubilant Ingrevia Share Price

713.25 11.30 (1.61%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3640.10
Tata Chemicals 809.45
SRF 2519.20
Pidilite Inds. 1375.55
Deepak Nitrite 1736.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×